Resources with keywords: omicron



Update on SARS CoV-2 Variant BA.2.86 (NEW 9/13, Website, Regulatory)
CDC
30 August 2023

CDC is tracking a new SARS-CoV-2 variant called BA.2.86 (Pirola) and working to better understand its potential impact on public health.

Effectiveness of Monovalent mRNA COVID-19 Vaccination in Preventing COVID-19–Associated Invasive Mechanical Ventilation and Death Among Immunocompetent Adults During the Omicron Variant Period — IVY Network, 19 U.S. States, February 1, 2022–January 31, 2023 (NEW 6/12, Website, Publication)
CDC/MMWR
28 April 2023

DeCuir J, Surie D, Zhu Y, et al.

Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, December 2022–January 2023 (Website, Regulatory)
CDC/MMWR
3 February 2023

Link-Gelles R, Ciesla AA, Roper LE, et al.

SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway (Website, Publication)
Nature Microbiology
7 July 2022

Willett BJ, Grove J, MacLean OA et al.

This study shows evasion of neutralization by Omicron BA.1 and BA.2 variants in vitro using sera from individuals vaccinated with ChAdOx1, BNT162b2 and mRNA-1273.

Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022 (NEW 3/7, Website, Publication)
CDC/MMWR
18 February 2022

Ferdinands JM, Rao S, Dixon BE, et al.

keywords: covid-19, Delta, mRNA, omicron
Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022 (NEW 3/7, Website, Publication)
CDC/MMWR
18 December 2021

Klein NP, Stockwell MS, Demarco M, et al.
Two doses protect against COVID-19–associated emergency department and urgent care encounters among children and adolescents. However, vaccine effectiveness (VE) was lower during Omicron predominance and decreased with time since vaccination; a booster dose restored VE to 81% among adolescents aged 16–17 years. Overall, 2-dose VE against COVID-19–associated hospitalization was 73%–94%.

Take a look at SARS-CoV-2's family tree. It's full of surprises (NEW 3/7, Website, News)
NPR
9 February 2022
SARS-CoV-2 Infection and Hospitalization Among Adults Aged ≥18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance — Los Angeles County, California, November 7, 2021–January 8, 2022 (NEW 3/7, Website, Publication)
CDC
4 February 2022

Danza P, Koo TH, Haddix M, et al.

Omicron summary relative to infection and hospitalization of adults.

HKUMed finds Omicron SARS-CoV-2 can infect faster and better than Delta in human bronchus but with less severe infection in lung (NEW 12/5, Website, News)
University of Hong Kong - LKS Faculty of Medicine
15 December 2021

Premiminary data indicates that Omicron infects and mulitplies 70x faster than the Delta variant, but causes a lower infection in the lung.

HKU microbiologists find that two doses of BNT162b2 (BioNTech ) or Coronavac (Sinovac) vaccines are inadequate against Omicron virus variants (NEW 12/5, Website, News)
University of Hong Kong
14 December 2021
Go to Top